MAPK1 and neoplasm: As a multi-tyrosine kinase inhibitor, sorafenib blocks the RAF-MEK-ERK pathway to inhibit tumor cell proliferation and interacts with vascular endothelial growth factor receptors to attenuate tumor angiogenesis.